Specifically, amplification of the HER2 gene (ERBB2) is found in approximately 10% to 20% of invasive breast carcinoma [4–5] and results in the overexpression of HER2 protein and is associated with a poor prognosis [6–8]. This evidence concerns the gene ERBB2 and invasive breast carcinoma.